VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before market hours. A conference call will be held at 8:30 a.m. ET to discuss the results and provide updates. VYNE specializes in developing innovative dermatological therapies, having received FDA approvals for AMZEEQ® and ZILXI™, both minocycline topical foams. The company emphasizes its commitment to improving patient lives through proprietary technologies.

Positive

• FDA approval of AMZEEQ® and ZILXI® enhances product portfolio.
• Upcoming conference call may provide positive updates and financial guidance.

Negative

• None.

BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call
Thursday, November 5th @ 8:30am Eastern Time
Toll Free:			800-289-0438
International:			323-794-2423
Conference ID:			9576782
Webcast:			http://public.viavid.com/index.php?id=142196

A replay of the call will be archived on the Company’s website at https://vynetherapeutics.com promptly after the conference call.

About VYNE Therapeutics Inc.
VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI™ (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at amzeeq.com and ZILXI’s Full Prescribing Information at zilxi.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Media Relations:
Bridgette Potratz
Zeno Group
312-358-2950
bridgette.potratz@zenogroup.com

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com

 

FAQ

When will VYNE report its third-quarter financial results?

VYNE will report its financial results for Q3 2020 on November 5, 2020.

What time is the VYNE conference call scheduled for?

The conference call is scheduled for 8:30 a.m. Eastern Time on November 5, 2020.

What are AMZEEQ® and ZILXI®?

AMZEEQ® and ZILXI® are FDA-approved topical minocycline foams developed by VYNE for dermatological use.

What is the ticker symbol for VYNE Therapeutics?

The ticker symbol for VYNE Therapeutics is VYNE.

How can I access the VYNE conference call?

You can access the VYNE conference call by dialing 800-289-0438 for toll-free or 323-794-2423 for international.